KR20120120912A - External compositions for prevention of hair loss and promotion of hair growth - Google Patents

Abstract

PURPOSE: A composition containing 5alpha-reductase inhibitors and minoxidil is provided to prevent hair loss and promote hair growth. CONSTITUTION: An external use composition for preventing hair loss and promoting hair growth contains 5alpha-reductase inhibitor, and minoxidil, or pharmacologically acceptable salts thereof. The daily dose of the 5-alpha reductase inhibitor applied by transdermal administration is 0.8 ug to 0.12 mg. The daily dose of minoxidil or pharmacologically acceptable salt thereof is 0.008g to 0.12g. The 5alpha-reductase inhibitor is finasteride, pharmacologically acceptable salt thereof, dutasteride, or pharmacologically acceptable salt thereof. The external use composition additionally contains alphatradiol. The external use composition further contains low molecular mono alcohol of 1-4 carbon atoms, polyvalent alcohol;, and water.

Description

EXTERNAL COMPOSITIONS FOR PREVENTION OF HAIR LOSS AND PROMOTION OF HAIR GROWTH}

The present invention relates to an external preparation composition for preventing hair loss and promoting hair growth, including a 5α-reductase inhibitor and minoxidil.

The causes of hair loss studied so far include excessive sebum production due to endocrine disorders such as hormonal imbalance, circulatory disorders such as autonomic nervous system and blood circulation disorders, malnutrition of hair roots, allergies, bacterial infections, genetic factors, mental stress, and atmosphere. It is estimated to be due to environmental factors such as pollution or food and aging. Alopecia has only occurred in the middle and middle age group in the past, but has recently occurred frequently among young people and women in their 20s and 30s.

The effects of a commercially available product on the hair as a hair growth or hair loss inhibitor on the hair include growth phase induction effect, hair growth phase extension effect, 5α-reductase inhibitory effect, blood circulation promoting effect, bactericidal effect, anti-dandruff effect, moisturizing effect, and antioxidant effect. And the like, but the effect of preventing hair loss and promoting hair growth is not sufficient in existing formulations.

Androgenetic alopecia is directly dependent on the amount of male hormone since it is dependent on male hormones, and thus, many studies have recently been reported to prevent and treat hair loss through the inhibition of male hormone activity. Briefly explain the mechanism of hair loss on male hormones are as follows. That is, testosterone, one of the male hormones, is converted to dihydrotestosterone, an active male hormone, by an enzyme called 5α-reductase, and the active male hormone binds to a certain receptor to cause hair loss. This leads to protein and leads to hair loss. In addition, such mechanisms may cause excessive production of sebum, causing acne, seborrheic dermatitis, and the like, and as a result, scalp may occur with inflammation. Consequently, androgenetic alopecia is due to the excessive production of dihydrotestosterone by the action of 5α-reductase, it is possible to fundamentally and effectively prevent and treat male alopecia if the activity of 5α-reductase is inhibited.

Currently, the most widely used drugs for the treatment of hair loss include 2,4-diamino-6-piperidinopyrimidine-3-oxide (also known as 'minoxidil' formulations, US patents). 4,139,619 and 4,596,812) oral preparations containing finasteride, which is a specific inhibitor of type II 5α-reductase.

The minoxidil was developed for the purpose of lowering blood pressure in hypertensive patients, but the use of the drug was changed to a hair regrowth medicine due to side effects of hair growth during use, and thus a drug used a lot. The mechanism of action of minoxidil, which was approved by the US Food and Drug Administration (FDA) in 1979 as a hair loss treatment, is not clear, but the hypothesis that it promotes hair growth by improving blood flow around the scalp hair follicles and promotes hair growth. The hypothesis is that it acts on the epithelium and causes hair growth. However, the hair refining agent including minoxidil is very cumbersome and difficult to forget because it has to be applied steadily several times daily to maintain the hair regrowth effect, and there are many cases in which sufficient hair regrowth effect is not obtained due to irregular application and arbitrary treatment discontinuation.

In addition, based on the action of the finasteride (Finasteride) on the male hormone, there is a method of preventing the hair thinning and thickening the thin hair again by the antagonism of the finasteride to 5α-reductase. One example is Propecia, which Merck, USA, was approved as the first to treat hair loss by the US Food and Drug Administration (FDA) in December 1997, and was approved as a drug for alopecia the following year. . Finasteride is a drug that inhibits the 5α-reductase enzyme, which converts testosterone, a type of testosterone, to dihydrotestosterone (DHT), which causes hair loss. This suppresses the baldness of the bald hair and serves to grow thick and long hair again. At the time of development, 1,879 people were tested in clinical trials, and 17% of the patients who had been using it continuously for two years did not develop any hair loss, and 83% had maintained or increased the number of hairs after treatment. However, it takes several months to prevent hair loss, women are more likely to have birth defects when taking it, and men have fears of side effects such as decreased libido, impotence and ejaculation disorders. There is a significant limitation in actual clinical use due to the burden of maintaining hair loss prevention effect.

Meanwhile, the US Food and Drug Administration (FDA) recently revised its permits regarding the persistence of some sexual function-related side effects after discontinuation of the drug containing 1 mg of finasteride, which is used to treat male alopecia, while giving caution to medical professionals and patients. It was. This was reviewed in the post-marketing cases reported in the US FDA Adverse Adverse Reporting System (AERS) and the safety database of the product license holder. According to a number of reported cases, no clear causal relationship has been established between these components and adverse effects on sexual function.

The present invention has been made to solve the problems of the prior art as described above,

(1) exhibits at least equivalent hair loss prevention and hair growth promoting effect while using a 5α-reductase inhibitor of 1/4 or less as compared to conventional therapeutics;

(2) almost no side effects of conventional therapeutics;

(3) The effect is manifested very quickly, effectively preventing hair loss from the beginning of treatment,

(4) An object of the present invention is to provide a topical composition for preventing hair loss and promoting hair growth, which has an effect of almost 100% for hair loss patients, unlike a conventional prescription which is effective only in about 70% of hair loss patients.

In order to solve the above object, the present invention provides a 5α-reductase inhibitor; And a minoxidil or a pharmacologically acceptable salt thereof, the composition for preventing hair loss and promoting hair growth is provided.

More specifically finasteride, dutasteride or pharmacologically acceptable salts thereof; And a minoxidil or a pharmacologically acceptable salt thereof, the composition for preventing hair loss and promoting hair growth is provided.

Hair loss prevention and hair growth promoting composition of the present invention is

While using a much smaller amount (less than 1/4) of drugs compared to conventional oral 5α-reductase inhibitors, it provides more than equivalent hair loss prevention and hair growth promoting effect,

In addition to using a small amount of drugs, it has a formulation in the form of external preparations, so there are almost no side effects such as decreased libido, impotence, ejaculation disorders,

Since the expression of the effect is much faster than when the conventional oral 5α-reductase inhibitor and minoxidil are used alone or in combination, respectively, it is possible to effectively prevent hair loss from the beginning of treatment and to improve the treatment compliance of patients. ,

Unlike conventional prescriptions, which only work in about 70% of hair loss patients, they exhibit almost 100% effect on hair loss patients.

Hereinafter, the present invention will be described in detail.

The present invention provides a 5α-reductase inhibitor; And a minoxidil or a pharmacologically acceptable salt thereof, and a topical composition for preventing hair loss and promoting hair growth.

The daily dose of the 5α-reductase inhibitor to be administered transdermally in the external preparation for hair loss prevention and hair growth is 0.8 μg-0.12 mg, and 1 of the oral tablet of dutasteride, a commercially available 5α-reductase inhibitor, is used. It is about one quarter or less compared to a daily dose of 0.5 mg (a daily dose of commercially available finasteride oral drug is 1 mg).

More preferably, the daily dose of the 5α-reductase inhibitor is 0.8 μg-0.05 mg, and even more preferably the daily dose of the 5α-reductase inhibitor is 0.001 mg-0.025 mg.

When the daily dose of the 5α-reductase inhibitor is less than 0.8 μg, the expression of the effect is insignificant, and when it exceeds 0.12 mg, side effects such as decreased libido and decreased ejaculation may occur.

The daily dose of minoxidil or a pharmacologically acceptable salt thereof, which is included in the external preparation for preventing hair loss and promoting hair growth, is transdermally administered, is 0.008 g-0.12 g. If the daily dose is less than 0.008 g, the desired effect may not be obtained. If the daily dose is greater than 0.12 g, side effects such as increased cardiac output during long-term use and an enlarged end volume of the left ventricle may be exhibited.

If the 5α-reductase inhibitor is finasteride or a pharmacologically acceptable salt thereof, the daily dose is 0.001 mg-0.12 mg, more preferably 0.005 mg-0.05 mg, even more preferably 0.005 mg- 0.025 mg. If the amount of finasteride or pharmacologically acceptable salt thereof is out of the above range, there is a possibility that the effect is insufficient or side effects occur.

If the 5α-reductase inhibitor is dutasteride or a pharmacologically acceptable salt thereof, the daily dose is 0.8 μg-0.06 mg, more preferably 0.0016 mg-0.025 mg, even more preferably 0.0016 mg-0.012 mg. If the amount of dutasteride or pharmacologically acceptable salt thereof is out of the above range, there is a risk of insufficient effects or side effects.

5α-reductase inhibitors have side effects such as decreased libido, impotence, and ejaculation disorders, and the FDA recently revised its permits regarding the persistence of these side effects even after discontinuation of medication, while advising medical professionals and patients. I did.

Therefore, it is desired to reduce the amount of 5α-reductase inhibitory drug in reality in order to minimize such side effects. Therefore, studies are being actively conducted to orally administer a 5α-reductase inhibitor drug to reach an accurate target. On the other hand, attempts have been made to administer the 5α-reductase inhibitor drug finasteride percutaneously, but no significant effect has been obtained.

The external preparation composition of the present invention dissolves the 5α-reductase inhibitor drug in the solvent together with minoxidil and then percutaneously to deliver the 5α-reductase inhibitor drug to the target by the synergistic effect thereof. It is almost 100% effective for hair loss patients, and (ii) it is important to provide a much faster and better effect while using a much smaller amount of 5α-reductase inhibitor drug of less than 1/4 compared to conventional prescription. It features.

Such remarkable effects are thought to be due to the significantly improved transdermal delivery efficiency of the 5α-reductase inhibitory drug by the vasodilating effect of minoxidil.

The 5α-reductase (reduced nicotinamide adenine dinucleotide phosphate: Δ4-3-ketosteroid 5-alpha-oxidoreductase) is present as an isozyme of type I and type II, and in testosterone Promotes reductive conversion to 5 alpha-dihydrotestosterone. Testosterone is primarily responsible for determining the internal genital structure of men, and dihydrotestosterone is required for the external genitalia to differentiate.

Type I 5α-reductase is mainly distributed around the sebaceous gland and type II 5α-reductase is found in the dermal papilla and lateral hair follicles of hair follicles, which are important for hair follicle growth. Dihydrotestosterone (DHT) produced by 5α-reductase binds to hair follicle receptors and the DHT-receptor complex enters the cell nucleus, causing DNA to affect the proliferation and differentiation of hair follicle cells. Induces production Many of the regulatory substances produced by DHT accelerate the growth of mosquito-cells, thereby accelerating the growth phase (growth stage 1-growth stage 5), and relatively shortening the differentiation of hair follicle cells (growth stage 6-degenerative) to promote hair loss and May lead to inhibition of hair growth.

The 5α-reductase inhibitor is preferably finasteride, dutasteride or a pharmacologically acceptable salt thereof.

The finasteride inhibits only the type I isozyme of 5α-reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT), and the dutasteride is a type I, type II isozyme of 5α-reductase Inhibits all and has a strong testosterone retention effect, thereby suppressing hair loss.

The structure of finasteride is represented by the following formula (1).

[Formula 1]

The structure of dutasteride is represented by the following formula (2).

[Formula 2]

The minoxidil is a lipophilic component that has excellent ability to penetrate the hair roots compared to other external preparations, and improves the blood flow around the scalp hair follicles and serves to supply useful nutrition for hair growth. Topical medication received.

The structure of minoxidil is shown in the following formula (3).

(3)

The external composition for preventing hair loss and promoting hair growth may be prepared to contain, for example, 0.1 mg to 5 mg, more preferably 0.1 mg to 2 mg of finasteride or a pharmacologically acceptable salt thereof with respect to 100 ml of the external preparation composition. In addition, it may be prepared to include 0.5 g to 5 g of minoxidil or a pharmacologically acceptable salt thereof with respect to 100 ml of the external preparation composition.

In addition, the external composition for preventing hair loss and promoting hair growth is prepared to include 0.05 mg to 2.5 mg, more preferably 0.1 mg to 1.0 mg of dutasteride or a pharmacologically acceptable salt thereof, for example, with respect to 100 ml of the external preparation composition. Can be. It may also be prepared to contain 0.5 g to 5 g of minoxidil or a pharmacologically acceptable salt thereof with respect to 100 ml of the external preparation composition.

The external preparation composition prepared as described above is preferably used by applying 100 ml once a day twice or twice a day for 45 days to 60 days.

Finasteride, dutasteride and minoxidil of the present invention can be used in the form of pharmacologically acceptable salts, and acid addition salts formed by pharmacologically acceptable free acid are useful as salts. Acid addition salts include those derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates, Dioleate, aromatic acid, aliphatic and aromatic sulfonic acids. These pharmacologically toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide and iodide. Id, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suverate , Sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxybenzoate, meth Oxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzene Fonates, xylenesulfonates, phenyl acetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1 Sulfonates, naphthalene-2-sulfonates or mandelate.

The external composition for preventing hair loss and promoting hair growth may further include estradiol for women, and may preferably further include alpha tradiol (Alfatradiol, 17α-estradiol).

The alpha tradiol is an estrogen derivative, which can prevent the conversion of testosterone to dihydrotestosterone and promote the proliferation of hair follicle cells. In particular, it can be effectively used for the treatment of female alopecia patients.

The solvent of the external preparation composition for preventing hair loss and promoting hair growth can be used as long as it is commonly used in the art, for example, water; Lower mono alcohols having 1 to 4 carbon atoms including methanol, ethanol, isopropyl alcohol and butanol; Polyhydric alcohols including ethylene glycol, propylene glycol and 1,3-butylene glycol; And one or two mixtures selected from the group consisting of glycerin.

In particular, it is preferred to include lower mono alcohols, polyhydric alcohols, and water having 1 to 4 carbon atoms for efficient delivery of the drug.

As the lower mono alcohol having 1 to 4 carbon atoms in the above, ethanol may be preferably used, but is not limited thereto, and propylene glycol may be preferably used as the polyhydric alcohol.

When the solvent contains a lower mono alcohol having 1 to 4 carbon atoms, polyhydric alcohol, and water, 10 to 60% by volume lower mono alcohol having 1 to 4 carbon atoms, 3 to 20% by volume polyhydric alcohol, and relative to the total volume of the solvent, and It is preferable to include the residual amount of water, more preferably 30 to 50% by volume of lower mono alcohols having 1 to 4 carbon atoms, 5 to 15% by volume of polyhydric alcohol, and the remaining amount of water.

If the solvent has such a composition ratio, the transdermal delivery efficiency of the drug is greatly increased.

The external preparation composition for preventing hair loss and promoting hair growth of the present invention may be prepared in any formulation as long as it can be applied to the scalp such as liquid or gel type, hair tonic, scalp treatment, hair cream, general ointment, lotion, powder, It is preferably prepared in one or more formulations selected from the group consisting of essences, packs, hair dyes, shampoos, rinses, lotions, gels, patches or spray types, more preferably in spray or gel type. .

The components such as finasteride, dutasteride and minoxidil may increase the amount of systemic absorption when the amount used is increased, which may increase the possibility of side effects. The present invention uses a much smaller amount than the amount of finasteride, dutasteride or minoxidil used in the conventional hair growth promoter, and can selectively minimize side effects through local absorption, as well as significantly prevent hair loss. It shows the effect and the hair growth effect is also remarkably excellent.

In addition, in the case of conventional oral administration, the treatment failure rate due to the irregular dosage is high, while the method of applying the composition of the present invention as a spray type shows the effect of reducing concern about side effects, increasing hair thickness, and reducing hair loss. It is easy to apply and the patient's compliance is high, so the treatment success rate is high.

The external preparation composition for preventing hair loss and promoting hair growth comprising finasteride and minoxidil is mainly for men, and the external preparation composition containing low concentration finasteride and minoxidil can be used for non-fertile women.

The external composition for preventing hair loss and promoting hair growth comprising dutasteride and minoxidil may be used for males or non-fertile women.

In addition, the external preparation composition may further include excipients commonly used in the art within the scope of not impairing the object and effect of the present invention, preferably a group consisting of a pH adjuster, a solubilizer and combinations thereof It may further comprise a pharmaceutically acceptable excipient selected from.

The pH adjusting agent may be selected from the group consisting of citric acid, malic acid, lactic acid, phosphoric acid, hydrochloric acid, sulfuric acid, and combinations thereof, but is not limited thereto.

The solubilizer may be selected from the group consisting of diethylene glycol monoethyl ether, benzyl alcohol, glycerin, octoxynol, propylene glycol, propylene carbonate, polyethylene glycol, and mixtures thereof, but is not limited thereto.

Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. However, the following examples and test examples are for illustrating the present invention more specifically, but the scope of the present invention is not limited by the following examples and test examples.

Example  1 to 6: Preparation of external preparation composition for preventing hair loss and promoting hair growth

Ethanol, propylene glycol and water were mixed at a volume ratio of 4: 1: 5, and then the pinnasteride or dutasteride and minoxidil were dissolved in the mixed solution at the capacity of the following Table 1 to prevent hair loss and promote hair growth of Examples 1 to 6. for 100 ml of the external preparation composition was prepared.

ingredient Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Finasteride 1 mg
(0.001%) 1 mg
(0.001%) 2 mg
(0.002%) 2 mg
(0.002%) - - Dutasteride - - - - 0.2 mg
(0.0002%) 0.5 mg
(0.0005%) Minoxidil
5 g (5%) 2 g (2%) 2 g (2%) 5 g (5%) 2 g (2%) 2 g (2%)

Note)% concentration in the present invention means w / v% concentration.

Comparative example  1-3.

Comparative Examples 1 to 3 may be obtained by purchasing a commercial finasteride oral drug, dutasteride oral drug, and minoxidil transdermal drug containing a dose as described in Table 2 below, or combining oral drug and transdermal drug, or transdermally. It was prepared to have a single composition.

ingredient Comparative Example 1 Comparative Example 2 Comparative Example 3 Finasteride Oral Dosing Agent 1 mg - Dutasteride oral administration (mg) - 0.5 Minoxidil Scalp Coating Agent (%) 5% 5% 5%

Test Example  1: Clinical trial on hair loss prevention and hair growth promoting effect

1) Evaluation of change in hair thickness and hair count

100 ml of the external preparation composition of Examples 1 to 6 was sprayed onto the scalp of the bald area of the alopecia patient twice a day (morning and evening) and confirmed its effect. 100 ml of the external preparation composition of Examples 1 to 6 were used for about 45-60 days, and after being used up, they were prepared and used in the same manner as above. In the case of the formulations of Comparative Examples 1 and 2, oral administration was administered once a day to alopecia patients, and a minoxidil external preparation was applied to the scalp of the hair loss site and the expected hair loss site twice a day, and the effect thereof was confirmed. In the case of the formulation of Comparative Example 3, a minoxidil external preparation was applied twice a day to alopecia and anticipated alopecia of alopecia patients, and the effect thereof was confirmed.

The patient with alopecia was selected according to the selection and exclusion criteria described in Table 3 below, and when the first visit to the hospital, the hair condition was diagnosed, the hair loss site was marked and recorded, and the black spots on the most severe areas were tattooed to make the same. Measures were taken to allow site measurements. Then, the number of hairs per unit area (hair count / cm 2) and hair thickness (μm) of the hair loss site were measured using a simple hand-held phototrichogram (Folliscope, Lead M Co, Seoul, Korea). For the number of hairs per unit area, the number of terminal hairs in the unit area was calculated after photographing the hair loss around the display area using a 30x lens. The thickness of the hair was set to the average value after measuring the thickness of five strands around the display area using a 200 times lens.

Changes in the number of hairs (the number of hairs / cm 2) and the thickness of the hairs (μm) measured before and after drug administration of the alopecia patients were shown in Tables 4, 5, and 7 below, and the significance of these data was shown. Was tested by T-TEST (including F-TEST). T-TEST (including F-TEST) assay results are shown in Tables 6 and 8.

Alopecia Patient
Selection criteria ① Alopecia male or female alopecia diagnosed with androgenetic alopecia aged 18-60 years
Patients with androgenetic alopecia diagnosed with basic type M2 or more or C2 or U1 or more, and specific type V1 or more or F1 or more according to the Basic and specific (BASP) classification
③ Patients who will not perform special hair care or hair care and manipulation during the study period.
Patients who will maintain the same hair during the study
⑤ Male patient who has recently progressed hair loss Alopecia Patient
Exclusion Criteria ① Has suffered from severe acute kidney or heart disease or other chronic disease (hypertension, diabetes, etc.) that may affect test results in the last 6 months
② Those with psychiatric diseases
③ Those who have infectious skin disease
④ Those who have undergone surgical treatment for hair loss such as hair transplantation or scalp reduction
⑤ Have been using oral Finasteride or Oral Dutasteride for last 12 months
⑥ Applicants who have applied topical hair regrowth, wool and hair growth agents for the last 6 months
⑦ A person who is suspected of having trouble applying test substance due to severe seborrheic dermatitis, scalp psoriasis, scalp infection, etc.
⑧ Patients with other alopecia, such as alopecia areata, resting alopecia, scarring alopecia, in addition to androgenetic alopecia
⑨ Other than the above items, a person deemed difficult to perform the test due to the judgment of the person in charge of the test.

Composition ratio Measurement point 2 weeks 4 weeks 6 weeks 7 weeks 8 weeks Example 1 finasteride 0.001%
+ minoxidil 5% One Increased hair count 23 Increased hair thickness (㎛) 0.012 Example 2 finasteride 0.001%
+
minoxidil 2% One Increased hair count 29 Increased hair thickness (㎛) 0.002 2 Increased hair count 26 Increased hair thickness (㎛) 0.012 3 Increased hair count 19 Increased hair thickness (㎛) 0.009 4 Increased hair count 13 16 Increased hair thickness (㎛) 0.028 0.03 5 Increased hair count 4 9 Increased hair thickness (㎛) 0.006 0.012 6 Increased hair count 3 8 Increased hair thickness (㎛) 0.003 0.004 7 Increased hair count One 9 Increased hair thickness (㎛) 0.004 0.006 8 Increased hair count 3 8 Increased hair thickness (㎛) 0.003 0.004 9 Increased hair count -5 6 Increased hair thickness (㎛) 0.004 0.007 10 Increased hair count 3 10 Increased hair thickness (㎛) 0.003 0.011 11 Increased hair count 11 19 Increased hair thickness (㎛) 0.005 0.01 Example 3 finasteride 0.002%
+ minoxidil 2% One Increased hair count 24 Increased hair thickness (㎛) 0.012 2 Increased hair count 35 Increased hair thickness (㎛) 0.021 Comparative Example 1 finasteride 1mg
+
minoxidil 5% One Increased hair count -39 Increased hair thickness (㎛) -0.007 2 Increased hair count 3 Increased hair thickness (㎛) 0.001 3 Increased hair count 4 Increased hair thickness (㎛) 0.002

Note) The part in which the data is not described in the above table indicates that the measurement of the number of hairs and the hair thickness was not made at that time. This point also applies to the following tables.

The data shown in Table 4 is data for confirming the rapid effect expression of the external preparation composition of the present invention. In other words, the data in Table 4 shows that almost all alopecia patients (9 patients dosed with the composition of Example 2) whose changes in hair number and hair thickness were measured at 2 to 4 weeks after the external composition of the present invention was administered. Shows a marked increase in hair count and hair thickness. However, one patient showed a decrease in hair count at 4 weeks of measurement, and this patient also showed an increase in hair count at 8 weeks of measurement.

In addition, the data of Table 4 shows that all the alopecia patients (13 patients dosed with the compositions of Examples 1 to 3) whose changes in hair number and hair thickness were measured after 6 to 8 weeks of administration of the external preparation composition of the present invention. ) Also shows a marked increase in hair count and hair thickness.

This effect, as is well known in the art, is very surprising given that at least three months must occur at least in conventional formulations to prevent hair loss or hair growth (see data in Comparative Example 1).

Specifically, according to the data in Table 4, the alopecia patients dosed with the external preparation compositions of Examples 1 to 3 of the present invention have a very significant increase in hair count compared to the alopecia patients who received the prescription of Comparative Example 1, which is a conventional prescription. An increase in hair thickness was shown. That is, the alopecia patient administered the external preparation composition of the present invention showed a very significant hair number and hair thickness increase effect from 2 weeks of administration, the effect gradually increased over time, Comparative Example 1 at the end of 8 weeks Compared to the alopecia patients who received the prescription of, the difference was more pronounced.

The rapid effect expression of the external preparation composition of the present invention as described above indicates that the external preparation composition of the present invention can greatly improve the treatment compliance and satisfaction of the patient. That is, in the case of the conventional prescription, many patients give up treatment during the treatment because the effect appears too late, but when using the composition of the present invention, it indicates that such a problem can be solved significantly.

In addition, the results of the above clinical trials can be seen to suggest not only the excellent effect that can be obtained when using the external preparation composition of the present invention, but also the possibility of using the combination with a conventional oral preparation.

That is, in the case of the conventional prescription, the user's satisfaction is not high because the hair loss prevention and hair growth promoting effect is not sufficiently expressed until the point of 3 months from the time of use, and these results lower the patient's compliance with the treatment and give up the treatment. Cause results. However, in the case of combining the external preparation of the present invention and the conventional oral preparation, according to the characteristics of the external preparation of the present invention, a rapid hair loss prevention and hair growth promoting effect is shown even at the beginning of treatment, greatly improving the patient's treatment compliance and satisfaction, thereby treating intermediate treatment. The chance of abandonment is greatly reduced.

No. Medication Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 3 finasteride 0.001% +
minoxidil
5% finasteride 0.001% +
minoxidil
2% finasteride 0.002% +
minoxidil
2% finasteride 0.002% +
minoxidil
5% finasteride 1mg
+
minoxidil
5% minoxidil
5% Measurement point 13 Weeks 13 Weeks 13 Weeks 13 Weeks 13 Weeks 13 Weeks One Increased hair count 15 29 32 16 -26 10 Increased hair thickness (㎛) 0.009 0.006 0.035 0.019 -0.015 0.005 2 Increased hair count 22 45 44 19 -3 9 Increased hair thickness (㎛) 0.006 0 0.016 0.017 0.012 0.001 3 Increased hair count 9 21 29 32 One 11 Increased hair thickness (㎛) 0.007 0.011 0.006 0.035 0.002 0.01 4 Increased hair count 9 6 39 35 9 13 Increased hair thickness (㎛) 0.015 0.009 0.019 0.021 0.005 0.005 5 Increased hair count 19 5 9 24 -31 Increased hair thickness (㎛) 0.019 0.008 0.009 0.026 -0.016 6 Increased hair count 26 21 20 3 Increased hair thickness (㎛) 0.021 0.019 0.024 -0.005 7 Increased hair count 19 32 -12 Increased hair thickness (㎛) 0.009 0.026 -0.012 8 Increased hair count 26 19 -11 Increased hair thickness (㎛) 0.021 0.019 -0.019 9 Increased hair count 20 -6 Increased hair thickness (㎛) 0.033 0.02 10 Increased hair count 21 -11 Increased hair thickness (㎛) 0.019 -0.016 11 Increased hair count 10 Increased hair thickness (㎛) 0.005 12 Increased hair count -One Increased hair thickness (㎛) 0.001 13 Increased hair count 14 Increased hair thickness (㎛) 0.02 14 Increased hair count 10 Increased hair thickness (㎛) 0.002 Increased hair count
Average 16.6667 21.2 27.375 23.8 -4.75 0.5714 Increased hair thickness (㎛)
Average 0.0128 0.0068 0.0168 0.0239 0.001 0.000071

Hair count data TTEST Kinds Comparative Example 1 Data Comparative Example 3 Data Example 1 Data FTEST 0.130013191 0.166204493 TTEST 0.01472931 0.011818468 Example 2 Data FTEST 0.894114552 0.458770619 TTEST 0.046499133 0.012058313 Example 3 Data FTEST 0.475819066 0.69761868 TTEST 0.001838518 0.000102744 Example 4 Data FTEST 0.051284979 0.048452534 TTEST 0.000267943 0.000014812 Hair thickness data TTEST Kinds Comparative Example 1 Data Comparative Example 3 Data Example 1 Data FTEST 0.162697573 0.162697573 TTEST 0.040829245 0.016450776 Example 2 Data FTEST 0.082456882 0.049214765 TTEST 0.323896199 0.096803766 Example 3 Data FTEST 0.573873721 0.432576185 TTEST 0.027277192 0.003679183 Example 4 Data FTEST 0.130017138 0.040734435 TTEST 0.000342343 0.000004976

* p <0.05 is considered significant

As shown in Table 5, the external preparation composition of Examples 1 to 4 of the present invention is compared to the changes in hair count and hair thickness measured 13 weeks after administration compared to the conventional formulation Comparative Examples 1 and 3 In most cases, there was a marked increase. In addition, as a result of the assay by TTEST of Table 6, all of these results were found to be significant except the data of Example 2 among the hair thickness data.

The results of the above clinical trials are very important in that the topical composition of Examples 1 to 4 of the present invention showed a more significant hair loss prevention and hair growth promoting effect while using a much smaller amount of finasteride compared to the conventional prescription example. Have

That is, when orally administered finasteride (1mg / 1 day), side effects such as decreased libido, impotence, ejaculation disorder, etc. have been reported, the external preparation composition of the present invention has a superior effect while significantly reducing the dosage of finasteride Since it provides, it can be seen to present a breakthrough solution that can reliably solve the conventional side effects.

No. Medication Example 5 Example 6 Comparative Example 2 dutasteride
0.0002% +
minoxidil2% dutasteride
0.0005% +
minoxidil2% dutasteride
0.5mg +
minoxidil5% Measurement point 4 weeks 8 weeks 4 weeks 8 weeks 4 weeks 8 weeks One Increased hair count 29 45 11 10 4 11 Increased hair thickness (㎛) 0.019 0.018 0.301 -0.286 0.002 0.006 2 Increased hair count 10 26 19 16 -16 5 Increased hair thickness (㎛) -0.003 0.008 0.028 -0.001 -0.011 -0.003 3 Increased hair count 10 17 3 19 One 8 Increased hair thickness (㎛) 0.003 0.01 0.016 0.019 0.001 0.008 4 Increased hair count 13 22 2 22 -One 6 Increased hair thickness (㎛) 0.006 0.005 0.01 0.011 -0.022 -0.01 5 Increased hair count 29 45 6 7 Increased hair thickness (㎛) 0.014 0.013 0.003 0.535 6 Increased hair count 6 21 Increased hair thickness (㎛) -0.005 0.003 7 Increased hair count 16 Increased hair thickness (㎛) 0.408 Increased hair count
Average 18.2 31 7.8333 15.8571 -3 7.5 Increased hair thickness (㎛)
Average 0.0078 0.0108 0.0588 0.0984 -0.0075 0.00025

Hair count data TTES Kinds Comparative Example 2 Data (8 weeks) Example 5 Data FTEST 0.024723978 TTEST 0.014726095 Example 6 Data FTEST 0.248152042 TTEST 0.021595279 Hair thickness data TTEST Kinds Comparative Example 2 Data (8 weeks) Example 5 Data FTEST 0.685354662 TTEST 0.049411807 Example 6 Data FTEST 0.000082551 TTEST 0.38806212

* p <0.05 is considered significant

As confirmed in Table 7, the external preparation composition of Examples 5 to 6 of the present invention showed a remarkable hair count and increase and an increase in hair thickness (µm) as compared to Comparative Example 2, which is a conventional prescription. In addition, these results were confirmed to be significant except for the data of Example 6 among the hair thickness data of the test results by TTEST in Table 8.

The results of the above clinical trials are very important in that the external preparation compositions of Examples 5 and 6 of the present invention showed more significant hair loss prevention and hair growth promoting effects while using a much smaller amount of dutasteride as compared to the conventional prescription example. Has meaning.

In other words, when oral administration of dutasteride (0.5mg / day), side effects such as decreased libido, erectile dysfunction, ejaculation disorder, etc. are reported, the external preparation composition of the present invention significantly increases the dosage of dutasteride Since it provides a superior effect while reducing, it can be seen to present a breakthrough solution that can reliably solve the conventional side effects.

In addition, the change in the number of hair and the thickness of the hair (μm) in the clinical trial was measured at 4-8 weeks after the administration of the drug, the external preparation composition of Examples 5 and 6 of the present invention is very remarkable compared to the conventional formulation The effect shows that the effect expression of the external preparation composition of this invention is very quick.

These clinical trial results indicate that the topical composition of the present invention can greatly improve the patient's treatment compliance and satisfaction due to the speed of effect. That is, in the case of the conventional prescription, many patients give up treatment during the treatment because the effect appears too late, but when using the composition of the present invention, it indicates that such a problem can be solved significantly.

In addition, the results of the above clinical trials, as mentioned in Examples 1 to 4 above, as well as the excellent effect that can be obtained at the time of using the external preparation composition of the present invention alone, the possibility of combined use with conventional oral preparations It can be seen as presenting.

Test Example  2: effect expression rate and side effects evaluation

Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Comparative Example 1 Comparative Example 2 Comparative Example 3 Test group population 9 7 10 13 6 8 6 5 19 No effect
Treatment giver 0 0 0 0 0 0 One 0 3 Due to director
Treatment giver 0 0 0 0 0 0 0 One 0

Note) The above data is based on 32 weeks from the start of treatment.

As shown in Table 9, 100% effect was expressed in the alopecia patients who administered the external preparation composition of Examples 1 to 6 of the present invention, and the temporary scalp sensation occurred in two patients, but no side effects occurred. .

On the other hand, in the case of the conventional prescription Comparative Examples 1 to 3, 13% (4 people) out of the total test group population (30 people) gave up treatment due to the unexpressed effect, side effects about 3.3% (1 person) ). The results of Comparative Examples 1 to 3 above seem to correspond to the known facts regarding the effect unexpressed and the side effects.

Claims (9)

5α-reductase inhibitors; And a minoxidil or a pharmacologically acceptable salt thereof, the composition for preventing hair loss and promoting hair growth. The method of claim 1, wherein the daily dose of the 5α-reductase inhibitor to be administered transdermally included in the anti-hair loss and hair growth promoting external preparation is 0.8 μg-0.12 mg, the external composition for hair loss prevention and hair growth. The method of claim 2, wherein the daily dose of the 5α-reductase inhibitor which is included in the external preparation for preventing hair loss and promoting hair growth is 0.8 µg-0.05 mg, wherein the external composition for preventing hair loss and promoting hair growth is characterized in that. The method of claim 2, wherein the daily dose of the minoxidil or pharmacologically acceptable salt thereof contained in the external preparation for preventing hair loss and promoting hair growth is 0.008 g-0.12 g, wherein the external composition for preventing hair loss and promoting hair growth . The method of claim 1, wherein the 5α-reductase inhibitor is a finasteride or a pharmacologically acceptable salt thereof, the composition for preventing hair loss and promoting hair growth. The method of claim 1, wherein the 5α-reductase inhibitor is a dutasteride or a pharmacologically acceptable salt thereof, the composition for preventing hair loss and promoting hair growth. The external preparation composition for preventing hair loss and promoting hair growth according to claim 1, wherein the external preparation composition further comprises alpha tradiol. The external preparation composition for preventing hair loss and promoting hair growth according to claim 1, wherein the external preparation composition further comprises a solvent containing a lower mono alcohol having 1 to 4 carbon atoms, polyhydric alcohol, and water. The method of claim 1, wherein the formulation of the external preparation composition is from the group consisting of hair tonic, scalft treatment, hair cream, general ointment, lotion, powder, essence, pack, hair dye, shampoo, rinse, lotion, gel, patch and spray type Hair loss prevention and hair growth promoting external composition, characterized in that one selected.